Skip to main content

Table 1 General characteristics, clinical preoperative data, and preoperative medication

From: Terlipressin infusion for prevention of vasoplegic syndrome in patients treated with angiotensin II receptor antagonist undergoing coronary artery bypass graft surgery: a randomized controlled study

 

Terlipressin group (n = 50)

Placebo group (n = 50)

P value

Age (years)

55.8 ± 6.0

54.4 ± 5.6

0.26

Gender (M/F) (n)

40/10

43/7

0.44

Weight (kg)

71.8 ± 7.3

74.0 ± 8.6

0.17

Height (cm)

160.5 ± 5.7

158.6 ± 6.3

0.10

Ejection Fraction

52.8 ± 8.0

50.6 ± 6.9

0.14

Euro score II

1.1 ± 0.4

1.2 ± 0.3

0.36

Hypertension (n)

33

28

0.32

Diabetes mellitus (n)

21

26

0.42

Left main disease (n)

10

13

0.64

No. of diseased coronaries (2/3)

20/30

17/33

0.54

Losartan dose (mg/d)

52 ± 26.6

53.5 ± 32.3

0.80

β-blocker (n)

43

46

0.36

Calcium channel blocker (n)

7

5

0.76

Nitrate (n)

40

42

0.61

Diuretic (n)

9

11

0.63

  1. n number of patients, M/F male to female ratio
  2. Mean ± SD
  3. P value is significant when P < 0.05